SCHEMBL30730554

SCHEMBL30730554

Cc1nonc1CC(=O)N1CC2CCC(C1)C2c1nc(-c2ccc(F)cc2)no1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.51
LMNA P02545 4/20 0.51
MAPK1 P28482 2/20 0.51
ALOX15 P16050 1/20 0.51
GRM5 P41594 4/20 0.47
CLPP Q16740 1/20 0.47
MAPT P10636 1/20 0.45
HSD11B1 P28845 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HTT P42858 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30730611 0.94 TSHR (0.48) TSHRLMNAMAPK1ALOX15GRM5
SCHEMBL30730465 0.88 TSHR (0.56) TSHRLMNAMAPK1ALOX15GRM5
SCHEMBL30730662 0.85 LMNA (0.71) TSHRLMNAMAPK1ALOX15GRM5
SCHEMBL32676855 0.84 GRM5 (0.42) TSHRLMNAMAPK1ALOX15GRM5
SCHEMBL30730610 0.84 GRM5 (0.66) TSHRLMNAMAPK1ALOX15GRM5
SCHEMBL30730534 0.81 TSHR (0.48) TSHRLMNAMAPK1ALOX15GRM5
SCHEMBL30730664 0.81 PKM (0.42) GRM5HSD11B1ALDH1A1SMN1; SMN2PKM
SCHEMBL30730653 0.81 LMNA (0.53) TSHRLMNAMAPK1ALOX15GRM5
SCHEMBL30730471 0.80 LMNA (0.47) TSHRLMNAMAPK1ALOX15GRM5
SCHEMBL30730635 0.80 GRM5 (0.43) TSHRLMNAMAPK1ALOX15GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US claimed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO claimed
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE SCRIPPS RESEARCH INST (US) 2026-02-19 US disclosed
WO-2024030121-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048047-A1 SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE FNTB, PDE7A, TBL3 TSHR 620/4885LMNA 1838/4885MAPK1 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.